Quantification of Upadacitinib, Dasatinib, Ruxolitinib

Research record: Quantification of Upadacitinib, Dasatinib, Ruxolitinib, Imatinib, and Cabozantinib in Plasma With Liquid Chromatography-Tandem Mass Spectrometry.

Published in Ther Drug Monit; first publication date 2026-10-28. PMID 42949034.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Read the original publication on PubMed

Quantification of Upadacitinib, Dasatinib, Ruxolitinib, Imatinib, and Cabozantinib in Plasma With Liquid Chromatography-Tandem Mass Spectrometry.

Review and references

Explore more

MPT64 secretion as a viability-associated immunoassay readout for rapid phenotypic drug susceptibility classification of Mycobacterium tuberculosis: a proof-of-concept study.

Diagnostic performance of next-generation sequencing in thyroid nodules and molecular correlates of tumor aggressiveness in papillary thyroid carcinoma.

A Case of Recurrent COVID-19 Pneumonia Following Rituximab Therapy: Treatment Informed by a Serial Transbronchial Lung Cryobiopsy, BALF SARS-CoV-2 PCR, and the Clinical Course.